Navigation Links
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Date:7/9/2008

ieved to have superior anticoagulant effects compared to other targets such as thrombin. Portola believes betrixaban will offer several advantages over warfarin and the FXa inhibitors in development, including a long half-life to support once-daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment.

Portola has successfully completed a Phase 2 trial demonstrating betrixaban's proof of clinical concept and a favorable tolerability profile in preventing venous thromboembolism in patients undergoing knee replacement surgery. Later this year, Portola will initiate a Phase 2 clinical study in 500 patients comparing the safety and tolerability of betrixaban to warfarin, the only marketed chronic, oral anticoagulant for stroke prevention in patients with atrial fibrillation.

The other Phase 2 drug candidate is PRT060128, an antiplatelet agent that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit over clopidogrel and other antiplatelet agents in development through its immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola's clinical studies to date with the IV and oral formulations have shown that PRT060128 is well tolerated at high drug levels. Later this year, Portola will initiate a Phase 2 trial comparing the safety, tolerability and efficacy of the IV bolus followed by the oral formulation (60 days of therapy) of PRT060128 to clopidogrel in 800 patients undergoing elective percutaneous coronary interventions (PCI).

Expanding Early Stage Pipeline

Portola is developing a universal Factor Xa inhibitor antidote with the goal of neutralizing the effect of small molecule Factor Xa inhibitors in patients experiencing moderate or major ble
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Completes Bio-Distribution Studies
2. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
10. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
11. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... OAKS, Calif. , Jan. 22, 2015  Amgen (NASDAQ: ... and full year 2014 financial results on Tuesday, Jan. 27, 2015, ... be followed by a conference call with the investment community at ... Robert A. Bradway , chairman and chief executive officer, and ...
(Date:1/22/2015)... Increasing sophistication among enterprise buyers of language services ... 2015, says Moravia CMO, Renato Beninatto ... market research firm Common Sense Advisory, 15 percent of ... and localization needs. "From a language industry perspective, this ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced ... Source, Product & by End User - Global Forecast to ... global allergy diagnostics market is valued at $1,228.58 million in ... 12.67%, to reach $2,230.72 million by 2019. Allergy diagnostics is ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Netherlands, August 17 A new consortium has,been formed ... deadly,diseases, African sleeping sickness and Leishmaniasis, which affect millions,of ... euros has been,allocated over the next 4 years, to ... Pharmaceuticals, Mercachem, Nycomed,the Drugs for Neglected Diseases initiative, the ...
... , THOUSAND OAKS, Calif., Aug. 13 Amgen ... the outcome of today,s meeting with the U.S. Food and Drug ... the potential use of Prolia(TM) (denosumab) for the prevention and treatment ... in patients undergoing hormone ablation for either prostate cancer or breast ...
Cached Medicine Technology:New Consortium to Develop Drugs for Neglected Tropical Diseases 2Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting 2Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting 3Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting 4Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting 5Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting 6Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting 7Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting 8
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting ... auto insurance policy . , Some types of vehicles cannot ... the newly released blog post to see if their vehicle qualifies ... vehicles are some of the cars that cannot be covered by ...
(Date:1/22/2015)... Ga., USA (PRWEB) January 22, 2015 ... a statewide data management system with support from GEOSYSTEMS, ... , The new solution will leverage Hexagon Geospatial’s ... and vector data as well as point clouds and ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... 2010 In an effort that will contribute ... Philippines and surrounding regions, the Laboratory Services Division ... (FDA) has attained the internationally recognized accreditation for ... International Electrotechnical Commission (ISO/IEC) 17025:2005. The FDA celebrates ...
... Mich., July 12, 2010 Drinking tart cherry juice daily ... awake after going to sleep, according to a new study ... . A team of University of Pennsylvania, University of ... study on the sleep habits of 15 older adults. The ...
... a new international, peer-reviewed journal Drug Delivery and ... of drug delivery, the bi-monthly journal will provide a ... is an official journal of the Controlled Release Society ... will publish research on such topics as designing and ...
... - a set of dynamic factors that influence gene activity ... that affects boys, find researchers at Children,s Hospital Boston. The ... to hinge on an enzyme working in a biological pathway ... published online July 11 in the journal Nature , ...
... diabetes drug has shown promise in reducing body weight ... while avoiding the risk of psychiatric side effects that ... and stopped further development of other brain-penetrating drugs of ... that targeted the cannabinoid receptor CB1 such as ...
... Head and neck cancer patients who reported poor sleep ... pain and complaints of dry mouth related to radiation treatments, ... Comprehensive Cancer Center. Because these side effects can be ... in head and neck cancer patients may be warranted to ...
Cached Medicine News:Health News:Medicine quality in Philippines and region strengthened with Philippine FDA's accreditation 2Health News:New study suggests tart cherry juice can be a natural solution for insomnia 2Health News:Springer launches Drug Delivery and Translational Research 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 3Health News:Experimental obesity drug avoids brain effects that troubled predecessors 2Health News:Pain, dry mouth may play role in sleep quality of head and neck cancer patients 2Health News:Pain, dry mouth may play role in sleep quality of head and neck cancer patients 3
The combination of new measuring principle - Pupil Zone Imaging Method - and unique technology - SLD - offers high accuracy and reliability in refraction measurement....
... Module ACM-8 loads and unloads two centrifuges ... Identification via Cap Recognition the tube type ... in batches of three 5 position racks ... the single centrifuge ACM can be offered ...
... The Recapping System RCS 800 closes various ... efficient and easy way. Different tube heights and ... sealed tubes can be used for send-outs. The ... RSD 800, Aliquoting System RSD 800 and High ...
... detect sequences of the following viruses: ... and 3; influenza virus A and ... and B. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
Medicine Products: